VESPER-1 and interim VESPER-3 data release expected in September 2025; Phase 3 initiation on track for late 2025 MET-233i (once-monthly amylin analog) delivered ...

Nations that lead in clinical trials get earlier access to breakthrough therapies, shape global regulatory norms, and ...

A NEW “game-changing” drug could stop the progression of Alzheimer’s disease, early trials suggest. Scientists say the treatment – called trontinemab – could be the ...

Study to evaluate the efficacy and safety of fosmanogepix in adults with invasive mold infectionsStudy completion expected in ...

Study to evaluate the efficacy and safety of fosmanogepix in adults with invasive mold infectionsStudy completion expected in Q1 2028 Allschwil, Switzerland, July 29, 2025 ...

Trontinemab is one of a class of new medicines aimed at clearing amyloid plaques. The new findings from phase two trials ...

The Phase III VIKTORIA-1 trial (NCT05501886) is evaluating a triple combination of gedatolisib, Ibrance (palbociclib) and Faslodex (fulvestrant), a double combination of gedatolisib and Faslodex ...

A research project led by the Ineos Oxford Institute for antimicrobial research (IOI) to study the cause and impact of ...

Decentralized Clinical Trials (DCTs) are transforming how we collect clinical data, but this evolution brings unprecedented challenges in data quality, complexity, and integration.

Abivax dazzled investors and analysts with positive data from a pair of Phase III induction trials assessing obefazimod in adults with moderately to severely active ulcerative colitis. The results ...

The trial will test several treatment approaches in the maintenance setting for extensive stage small cell lung cancer.